New York University School of Medicine
New York, 10016, United States
NCT Number: NCT03820297
Approximately 50 participants will be enrolled and screened to achieve 45 eligible patients with mood/anxiety disorders to complete a 10 weekly anti-stigma group intervention (ASGI) in addition to several self-report internalized stigma and psychiatric measures.This study will examine changes in internalized stigma and psychiatric symptoms pre- and post-ASGI with 3 months post-intervention follow-up.
Looking for future studies?
Notify Me55 year and older
All sexes
Interventional
Not applicable
New York, 10016, United States
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
10-session intervention will occur weekly for 45 minutes per session: psychoeducation about mood and anxiety disorders, focusing on identification of risk factors and biological theory to counter stigma; psychoeducation regarding 'therapeutic modules' (psychotropics and psychotherapy) to treat depression, with an emphasis on the importance of psychiatric treatment adherence, providing behavioral strategies for anticipated and experienced forms of mental illness related work, social, or family discrimination
Time frame: 23 weeks
This 40-item self-report scale assesses the extent of patient self-stigma. Items are rated on a 9-point Likert-type scale (1= Strongly Disagree; 9= Strongly Agree).
Total score from 1 to 9 (average score) Higher score means worse outcome
Time frame: 23 weeks
Empowerment will be assessed using the 15-item scale from the Recovery Assessment Scale. This scale measures domains of recovery including 1) personal confidence and hope 2) willingness to ask for help 3) goal and success orientation 4) reliance on others 5) symptom coping. Patients are asked to describe themselves using a 5-point agreement scale (1= strongly disagree, 5= strongly agree) regarding their recovery.
Total score from15 to 75 (summed score) Higher score means better outcome
Time frame: 23 weeks
Changes in use of self-protective withdrawal and secrecy as a strategy for coping with public stigma will be evaluated using two scales to assess patients' responses to their stigmatized status.
Total score: 5 to 30 (summed score)
Total score: 6 to 42 (average score).
For the overall scale, summed score will be used. Higher score means better outcome
Time frame: 23 weeks
The subjective support and social interaction subscales from the Abbreviated Duke Social Support Scale (ADSSS) will be used to measure changes in social support. It is an 11-item Likert-type scalewhich has been shown to correlate well with mental and physical health outcomes.
Total score: 4 to 12 (summed score ).
Total score: 7 to 21 (summed score)
For the overall scale, total score from 11 to 33 (summed score of two subscales). A higher score means better outcome
Time frame: 23 weeks
The Patient Health Questionnaire-9 (PHQ-9) is a 9-item interview assessing depressive symptoms which is a reliable and valid measure of depression severity (0=not at all, 1=several days, 2=more than half the days, 3=nearly everyday).
Total score: 27 (summed score). A higher score means worse outcome
Time frame: 23 weeks
The Generalized Anxiety Disorder 7-item Scale (GAD-7) is a 7-item interview assessing anxiety symptoms (0=not at all, 1=several days, 2=more than half the days, 3=nearly everyday).
Total score: 21 (summed score will be used). A higher score means worse outcome
NYU Langone Health
Other
Effects Of Anti-Stigma Intervention For Chinese American Older Adults With Mood And Anxiety Disorders
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06282146
Anxiety Disorders, Behavior
Boston, Massachusetts, United States
View Trial DetailsNCT06364137
Anxiety Disorders, Mental Disorders
Stanford, California, United States
View Trial DetailsNCT05078450
Anxiety Disorders, Behavior
Ann Arbor, Michigan, United States
View Trial DetailsNCT05745103
Anxiety Disorders, Mental Disorders
Joplin, Missouri, United States
View Trial Details